Mei Pharma, Inc.

Mmrglobal, Inc.

The Spanish National Cancer Research Centre

The Immune Response Corporation

Aardvark Therapeutics, Inc.

Favrille, Inc.

Daniel P Gold

Robert J Shopes

Miguel Quintela-Fandino

Dennis J Carlo

Steven W Brostoff

Darcy B Wilson

Lawrence R Smith

Guillermo Garcia-Manero

Guillermo Garcia-manero

Provided herein are methods of treating and sensitizing cancer comprising administering a glycolytic inhibitor and an oxidative phosphorylation inhibitor.

Combination therapies

Provided herein are methods of treating diseases, such as cancer, using a combination therapy. In certain embodiments, the methods comprise administering an effective amount of a phosphoinositide-3-kinase (PI3K) inhibitor and an effective amount of a PD-1 or PD-L1 inhibitor to a patient.

Combination therapy

Provided herein are methods of treating diseases, such as cancer, using a combination therapy. In certain embodiments, the methods comprise administering an effective amount of a phosphoinositide-3-kinase (PI3K) inhibitor and an effective amount of a CD20 inhibitor to a patient.

The present invention provides compositions for altering a B cell mediated pathology in a patient. The compositions may comprise at least one and/or two chimeric proteins. Each chimeric protein comprises at least a portion of either the Vor Vregion of a immunoglobulin molecule from particular B cells from a patient having a B cell mediated pathology, and an immunoglobulin constant region. The genes encoding Vand/or Vregions and the genes encoding immunoglobulin constant regions are isolated and inserted in an expression vector. The chimeric proteins may be produced by introducing the expression vectors into insect cell lines. Proteins may be further purified and conjugated to a compound such as an immunogenic carrier.

Method and composition for altering a B cell mediated pathology

The present invention provides a method for altering a B cell mediated pathology in a patient. This method comprises administering a composition comprising at least one and/or two chimeric proteins. Each chimeric protein comprises at least a portion of either the Vor Vregion of a immunoglobulin molecule from particular B cells from a patient having a B cell mediated pathology, and an immunoglobulin constant region. The genes encoding Vand/or Vregions and the genes encoding immunoglobulin constant regions are isolated and inserted into an expression vector. The chimeric proteins are produced by introducing the expression vectors into insect cell lines. The chimeric proteins are purified using antibody affinity columns, and then chemically conjugated to an immunogenic carrier, keyhole-limpet hemocyanin (KLH). Since the conjugates comprise chimeric proteins made specifically from particular B cells from a patient having B cell mediated pathology, when it is administered to such a patient, with or without a cytokine, such as granulocyte-macrophage-CSF, or a chemokine, it can induce immune responses to alter such a B cell mediated pathology.

The present invention provides methods and compositions for altering a B cell mediated malignancy in a patient. These methods comprise administering a composition comprising at least one or two chimeric proteins. Each chimeric protein comprises at least a portion of either the Vor Vregion of the Id protein of the B cells associated with the B cell mediated malignancy, and an immunoglobulin constant region. The genes encoding Vor Vregions are isolated and inserted into an expression vector encoding immunoglobulin constant regions. The chimeric proteins are expressed in insect cell lines. The purified chimeric proteins are conjugated to an immunogenic carrier protein. The conjugates comprising the chimeric Id protein(s) are administered to such a patient, with or without a cytokine or chemokine, the chimeric protein induces immune responses to alter the B cell mediated malignancy.

The present invention provides vaccines and a means of vaccinating a mammal so as to prevent or control specific T cell mediated pathologies or to treat the unregulated replication of T cells. The vaccine is composed of a T cell receptor (TCR) or a fragment thereof corresponding to a TCR present on the surface of T cells mediating the pathology. The vaccine fragment can be a peptide corresponding to sequences of TCRs characteristic of the T cells mediating said pathology. The vaccine is administered to the mammal in a manner that induces an immunologically effective response so as to affect the course of the disease. The invention additionally provides specific &bgr;-chain variable regions of the T cell receptor, designated V&bgr;6.2/3, V&bgr;6.5, V&bgr;2, V&bgr;5.1, V&bgr;13 and V&bgr;7, which are central to the pathogenesis of multiple sclerosis (MS).

Growing community of inventors

Del Mar, CA, United States of America

Daniel P Gold